Harbour BioMed, a Cambridge, MA- Rotterdam, The Netherlands and Suzhou, China-based global, clinical-stage biopharmaceutical company, closed a $75 million (€67.4 million approx) Series B+ round of financing.
The round was led by new SK Holdings, Greater Bay Area Fund, Efung Capital, Zheshang Venture Capital and Zhejiang University Future Capital and JT New Century, which joined existing investors Legend Capital, AdvanTech and GIC Pvt. Ltd.
The company also previously completed an $85 million (approx €76 million) Series B financing in August 2018. Now it plans to use the funds to accelerate the advancement of its clinical-stage compounds and portfolio of biotherapeutics for treating cancer and immunological diseases.
Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, said in the press release,